A non‐inferiority comparative analysis of micro‐ultrasonography and MRI‐targeted biopsy in men at risk of prostate cancer

• Published in: BJU international 2022-05, Vol.129 (5), p.648-654
• Main Authors: Hofbauer, Sebastian L., Luger, Ferdinand, Harland, Niklas, Plage, Henning, Reimann, Maximillian, Hollenbach, Markus, Gusenleitner, Andreas, Stenzl, Arnulf, Schlomm, Thorsten, Wiemer, Laura, Cash, Hannes
• Format: Article
• Language: English
• Subjects: Biopsy; Comparative analysis; Magnetic resonance imaging; micro‐ultrasonography; multiparametric magnetic resonance imaging; PCSM; prostate biopsy; Prostate cancer; ProstateCancer; Sampling; targeted biopsy; Ultrasonic imaging; uroonc
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/bju.15635

Objective To compare the efficacy of multiparametric magnetic resonance imaging (mpMRI)‐directed and micro‐ultrasonography (micro‐US)‐directed biopsy for detecting clinically significant (Grade Group >1) prostate cancer (csPCa). Materials and Methods A total of 203 patients were prospectively enrolled at three institutions across Germany and Austria in the period from January 2019 to December 2019. During each biopsy, the urologist was blinded to the mpMRI report until after the micro‐US targets had been assessed. After unblinding, targets were then sampled using software‐assisted fusion, followed by systematic samples. The primary outcome measure was non‐inferiority of micro‐US to detect csPCa, with a detection ratio of at least 80% that of mpMRI. Results A total of 79 csPCa cases were detected overall (39%). Micro‐US‐targeted biopsy detected 58/79 cases (73%), while mpMRI‐targeted biopsy detected 60/79 (76%) and non‐targeted (completion sampling) samples detected 45/79 cases (57%). mpMRI‐targeted samples alone detected 7/79 (9%) csPCa cases which were missed by micro‐US‐targeted and non‐targeted samples. Three of these seven were anterior lesions with 2/7 in the transition zone. Micro‐US‐targeted samples alone detected 5/79 (6%) and completion sampling alone detected 4/79 cases (5%). Micro‐US was non‐inferior to mpMRI and detected 97% of the csPCa cases detected by mpMRI‐targeted biopsy (95% CI 80–116%; P = 0.023). Conclusions This is the first multicentre prospective study comparing micro‐US‐targeted biopsy with mpMRI‐targeted biopsy. The study provides further evidence that micro‐US can reliably detect cancer lesions and suggests that micro‐US biopsy might be as effective as mpMRI for detection of csPCA. This result has significant implications for increasing accessibility, reducing costs and expediting diagnosis.